title: Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain.
abstract: Proteolytic disruption of the extracellular matrix with opening of the blood-brain barrier (BBB) because of matrix metalloproteinases (MMPs) occurs in reperfusion injury after stroke. Matrix metalloproteinase inhibition blocks the early disruption of the BBB, but the long-term consequences of short-term MMP inhibition are not known. Recently, a method to quantify BBB permeability by graphical methods was described, which provides a way to study both early disruption of the BBB and long-term effects on recovery in the same animal. We used a broad-spectrum MMP inhibitor, BB1101, to determine both the usefulness of the Magnetic resonance imaging (MRI) method for treatment studies and the long-term effects on recovery. Magnetic resonance imaging studies were performed in control (N=6) and drug-treated (N=8) groups on a dedicated 4.7-T MRI scanner. Adult Wistar-Kyoto underwent a 2-h middle cerebral artery occlusion followed by an MRI study after 3 h of reperfusion, which consisted of T2- and diffusion-weighted techniques. Additionally, a rapid T1 mapping protocol was also implemented to acquire one pre-gadolinium-diethylenetriaminepentaacetic acid baseline data set followed by postinjection data sets at 3-min intervals for 45 mins. The same animal was imaged again at 48 h for lesion size estimation. Data was postprocessed pixel-wise to generate apparent diffusion coefficient and permeability coefficient maps. Treatment with BB-1101 significantly reduced BBB permeability at 3 h, but failed to reduce lesion size at 48 h. Behavioral studies showed impairment in recovery in treated rats. Magnetic resonance imaging allowed for the monitoring of multiple parameters in the same animal. Our studies showed that BB-1101 was an excellent inhibitor of the BBB damage. However, results show that BB-1101 may be responsible for significant deterioration in neurologic status of treated animals. Although these preliminary results suggest that BB-1101 is useful in reducing early BBB leakage owing to reperfusion injury in stroke, further studies will be needed to determine whether the later detrimental effects can be eliminated by shorter time course of drug delivery.
authors: Department of Neurology, University of New Mexico, Albuquerque, New Mexico 87131, USA. rsood@salud.unm.edu
authors: Rohit R
authors: RR
authors: Sood
authors: Saeid
authors: S
authors: Taheri
authors: Eduardo
authors: E
authors: Candelario-Jalil
authors: Eduardo Y
authors: EY
authors: Estrada
authors: Gary A
authors: GA
authors: Rosenberg
mesh_terms: D000818:Animals; D001593:Benzyl Compounds; D001812:Blood-Brain Barrier / Q000187:drug effects*; D003907:Dexamethasone / Q000627:therapeutic use*; D004338:Drug Combinations; D020244:Infarction, Middle Cerebral Artery / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D010431:Pentoxifylline / Q000627:therapeutic use*; D010539:Permeability / Q000187:drug effects; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D051381:Rats; D011921:Rats, Inbred WKY; D020127:Recovery of Function; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D013386:Succinates
chemical_list: C101468:BB 1101; D001593:Benzyl Compounds; D004338:Drug Combinations; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D013386:Succinates; D003907:Dexamethasone; D010431:Pentoxifylline
references: Magn Reson Med. 2000 Jun;43(6):837-44
references: 10861878
references: J Cereb Blood Flow Metab. 2007 Apr;27(4):697-709
references: 16850029
references: Nat Rev Neurosci. 2001 Jul;2(7):502-11
references: 11433375
references: Magn Reson Med. 2003 Aug;50(2):283-92
references: 12876704
references: Stroke. 2003 Aug;34(8):2025-30
references: 12855824
references: J Cereb Blood Flow Metab. 2004 Sep;24(9):945-63
references: 15356416
references: J Cereb Blood Flow Metab. 1983 Mar;3(1):8-32
references: 6822623
references: Neurology. 1984 Mar;34(3):315-20
references: 6546610
references: Acta Neuropathol. 1985;68(2):122-9
references: 3907257
references: Stroke. 1993 Mar;24(3):465-8
references: 8446984
references: J Cereb Blood Flow Metab. 1995 Nov;15(6):1002-11
references: 7593332
references: J Mol Med (Berl). 1997 May;75(5):341-7
references: 9181475
references: Nat Med. 1998 Feb;4(2):228-31
references: 9461198
references: Stroke. 1998 May;29(5):1020-30
references: 9596253
references: Am J Physiol. 1998 May;274(5 Pt 2):R1203-11
references: 9644031
references: Stroke. 1998 Oct;29(10):2189-95
references: 9756602
references: Ann Neurol. 1998 Oct;44(4):592-600
references: 9778257
references: J Cereb Blood Flow Metab. 1998 Nov;18(11):1163-72
references: 9809504
references: Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H558-68
references: 15764676
references: AJNR Am J Neuroradiol. 2006 Jan;27(1):51-4
references: 16418355
references: J Neurosci. 2006 Mar 29;26(13):3491-5
references: 16571756
references: Nat Med. 2006 Apr;12(4):441-5
references: 16565723
references: J Neurosci. 2006 May 31;26(22):5996-6003
references: 16738242
references: Exp Neurol. 2006 Jul;200(1):38-49
references: 16624294
references: Magn Reson Imaging. 2006 Oct;24(8):1039-49
references: 16997074
references: J Magn Reson Imaging. 2007 Jan;25(1):39-47
references: 17173307
references: J Cereb Blood Flow Metab. 2000 Oct;20(10):1474-82
references: 11043910